NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial

Summary

To learn if the proposed dose of 177Lu rhPSMA-10.1 is safe. Phase 2 will open if the Phase 1 dose is found to be safe. To learn about the safety and effects of 177Lu rhPSMA-10.1 alone and with androgen deprivation therapy (ADT) on patients with high-risk, localized prostate cancer before they have surgery to remove the disease.

Timeline

Start

2024-03-29

Primary completion

2026-12-31

Completion

2027-12-31

Drugs

Indications